Dr Reddy’s Laboratories has launched three products in the US market, namely, Donepezil Hydrochloride tablets (5mg and 10mg strengths), Venlafaxine Hydrochloride Extended Release capsules (37.5mg, 75mg and 150mg strengths) and Letrozole tablets, USP (2.5mg).
The Food & Drug Administration (FDA) approved Dr Reddy’s ANDA for Donepezil HCl tablets, a bioequivalent generic version of ARICEPT tablets, as on May 31, 2011. Both strengths of Dr Reddy’s Donepezil Hydrochloride tablets are available in 30, 90 and 500 count bottles.
Meanwhile, the FDA approved company’s ANDA for Venlafaxine Hydrochloride Extended Release Capsules, a bioequivalent generic version of EFFEXOR XR Extended Release capsules, as on May 05, 2011. All three strengths of Dr Reddy’s Venlafaxine Hydrochloride Extended Release Capsules are available in 30, 90 and 500 count bottles. Lastly, the FDA approved Dr Reddy’s ANDA for Letrozole tablets, USP, a bioequivalent generic version of FEMARA, on June 3, 2011. The company’s Letrozole tablets, USP are available in 30 count bottles.
According to IMS Health the ARICEPT brand and Donepezil Hydrochloride tablets generic version had total combined U.S. sales of approximately $2.3 billion for the twelve months ending March 31, 2011. The EFFEXOR XR brand and Venlafaxine Extended Release Capsules generic had total combined U.S. sales of approximately $2.3billion during the same period. Moreover, the FEMARA brand as reported had U.S. sales of approximately $702 Million for the twelve months ending March 31, 2011.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1664.80 |
| Dr. Reddys Lab | 1218.60 |
| Cipla | 1237.00 |
| Zydus Lifesciences | 931.90 |
| Lupin | 2304.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: